Ci­pla, Uni­taid ink pact to re­duce price of HIV drug

Chemical Industry Digest - - News & Views -

Drug ma­jor Ci­pla and Switzer­land-based Uni­taid have inked a pact un­der which the In­dian drug ma­jor would re­duce price of a com­bi­na­tion ther­apy which pre­vents in­fec­tions in peo­ple liv­ing with HIV.

Un­der the agree­ment, Ci­pla will re­duce the ceil­ing price of the medicine (Q-TIB) by more than 30 per­cent from USD 3 to USD 1.99 per per­son, per month, for all pub­lic-sec­tor pro­cur­ers in lowand mid­dle-in­come coun­tries.

The agree­ment would lead to re­duc­tion in price of Q-TIB, as gov­ern­ments and in­ter­na­tional fund­ing bod­ies pro­cure large quan­ti­ties for their HIV treat­ment pro­grammes.

The com­bi­na­tion ther­apy is a once-daily pill that pro­tects in three ways against TB, the lead­ing cause of death among peo­ple with HIV, and against other life-threat­en­ing bac­te­rial, and pro­to­zoan in­fec­tions.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.